Japan companion diagnostics market size is projected to exhibit a growth rate (CAGR) of 12.10% during 2024-2032. The rising incidence of cancer, the growing need for personalized medicine, and continuous technological advancements like next-generation sequencing (NGS), are among the primary factors propelling the market growth.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2023 |
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Growth Rate (2024-2032) | 12.10% |
Companion diagnostics refer to medical tests that aid physicians in identifying the most suitable treatment strategy. They are crafted to detect specific biomarkers present in a patient's tissue or blood sample, indicating whether the patient is likely to respond positively to a particular drug or therapeutic approach. Additionally, they delve into the intricate biological profile and mechanism of action (MOA) of patients, assisting healthcare professionals in comprehending potential medication side effects. The widespread application of companion diagnostics is evident in personalized medicine, where it takes into account the distinct characteristics of each patient, such as their genetic composition, to determine the optimal treatment course. Beyond this, there is a growing use of companion diagnostics for examining specific genetic mutations in cancer patients or identifying biomarkers in those with hepatitis C.
The Japan companion diagnostics market is experiencing significant growth, primarily propelled by the increasing incidence of diverse cancer types, which is fostering the demand for more precise and targeted cancer treatments. Additionally, the escalating demand for personalized medicines, tailored to the unique characteristics of each patient, further contributes to the optimistic market outlook. Simultaneously, the widespread adoption of targeted drugs and therapies addressing various infectious, cardiovascular, neurological, and inflammatory conditions serves as another substantial growth driver. The regulatory landscape for companion diagnostics in Japan is favorable, with an increasing number of tests receiving approvals. This, coupled with the expanding number of global clinical trials, strengthens the market growth. Ongoing advancements in diagnostic technologies, such as the emergence of next-generation sequencing (NGS) and liquid biopsy, are pivotal, enabling the identification of previously challenging-to-detect biomarkers. The development of innovative genomic technologies plays a key role, facilitating the identification of genetic mutations and biomarkers crucial for guiding treatment decisions, thereby fueling market growth. Additionally, factors like the growing use of biomarkers in drug development, substantial investments in precision medicine, and heightened consumer awareness regarding the benefits of companion diagnostics are projected to present lucrative growth opportunities for the regional market over the forecasted period.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on product & service, technology, indication, and end user.
Product & Service Insights:
The report has provided a detailed breakup and analysis of the market based on the product & service. This includes assays, kits and reagents and software and services.
Technology Insights:
A detailed breakup and analysis of the market based on the technology have also been provided in the report. This includes immunohistochemistry (IHC), polymerase chain reaction (PCR), in-situ hybridization (ISH), real-time PCR (RT-PCR), gene sequencing, and others.
Indication Insights:
The report has provided a detailed breakup and analysis of the market based on the indication. This includes cancer (lung cancer, breast cancer, colorectal cancer, gastric cancer, melanoma, and others), neurological diseases, infectious diseases, cardiovascular diseases, and others.
End User Insights:
A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes pharmaceutical & biopharmaceutical companies, reference laboratories, contract research organizations, and others.
Regional Insights:
The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Report Features | Details |
---|---|
Base Year of the Analysis | 2023 |
Historical Period | 2018-2023 |
Forecast Period | 2024-2032 |
Units | US$ Million |
Scope of the Report | Exploration of Historical and Forecast Trends, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment:
|
Product & Services Covered | Assays, Kits and Reagents, Software and Services |
Technologies Covered | Immunohistochemistry (IHC), Polymerase Chain Reaction (PCR), In-situ Hybridization (ISH), Real-time PCR (RT-PCR), Gene Sequencing, Others |
Indications Covered |
|
End Users Covered | Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, Contract Research Organizations, Others |
Regions Covered | Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, Shikoku Region |
Customization Scope | 10% Free Customization |
Report Price and Purchase Option | Single User License: US$ 3699 Five User License: US$ 4699 Corporate License: US$ 5699 |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |